Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14 Small Cell Lung Carcinoma 9 Carcinoma, Hepatocellular 9 Lung Neoplasms 8 Colorectal Neoplasms 7 Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Carcinoma, Renal Cell 4 Urinary Bladder Neoplasms 3 Triple Negative Breast Neoplasms 3 Solid Tumors 3 Sarcoma, Alveolar Soft Part 3 Neoplasm Metastasis 3 Melanoma 3 Breast Neoplasms 3 Small Cell Lung Cancer Extensive Stage 2 Sarcoma 2 Liver Neoplasms 2 Extensive Stage Lung Small Cell Carcinoma 2 Carcinoma, Transitional Cell 2 Carcinoma 2 Vaccinia 1 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Unresectable Hepatocellular Carcinoma 1 Stomach Neoplasms 1 Sarcoma, Clear Cell 1 Rhabdomyosarcoma 1

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × atezolizumab × 30 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡